SCHEMBL3247675

SCHEMBL3247675

CNc1nc(N2CCN(c3ccccn3)CC2)nc(N)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
HK1 P19367 1/20 0.57
HKDC1 Q2TB90 1/20 0.57
KDM4E B2RXH2 6/20 0.50
MAPT P10636 4/20 0.50
TSHR P16473 3/20 0.50
LMNA P02545 2/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DHFR P00374 2/20 0.46
POLB P06746 2/20 0.46
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HTR3A P46098 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240367 0.82 SORD (0.40) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL6664410 0.82 KDM4E (0.51) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL3243362 0.78 KDM4E (0.47) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL3244053 0.78 KDM4E (0.46) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL3246409 0.77 KDM4E (0.43) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL31254467 0.76 NPC1 (0.59) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL3247999 0.76 TNF (0.47) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL6783933 0.76 MEN1 (0.46) NPC1RAB9AKDM4EMAPTTSHR
SCHEMBL3238433 0.76 DHFR (0.42) NPC1RAB9AHK1HKDC1KDM4E
SCHEMBL5030785 0.75 RAB9A (0.63) NPC1RAB9AHK1HKDC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2140864-A2 Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods H.Lundbeck A/S (DK) 2010-01-06 EP disclosed
WO-2004034967-A2 2,4,6-TRIAMINOPYRIMIDINES FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2004-04-29 WO disclosed
WO-2004014307-A2 GAL3 ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2004-02-19 WO disclosed
WO-2004014376-A1 GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE DISORDERS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2004-02-19 WO disclosed
EP-1363638-A2 USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS Synaptic Pharmaceutical Corporation (US) 2003-11-26 EP disclosed
WO-2002060392-A2 USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2002-08-08 WO disclosed